TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33704435
Drug: Vaccinated patients
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated patients >0 days after 2nd dose
Study: 33205064
Drug: AKR-001 (Fc-FGF21
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKR-001 (Fc-FGF21 fusion protein) at 70 mg QW
Study: 34391872
Drug: Metformin (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (maximum dose 2,000 mg/d)
Study: 34376438
Drug: Transmuscular quadratus
Normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmuscular quadratus lumborum (TQL) block with 0.375% ropivacaine 20 mL on each side
Study: 34376438
Drug: Oblique subcostal
Normalized name: Inonotus obliquus fruiting body
DrugBank: Inonotus obliquus fruiting body (DB14332)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oblique subcostal transversus abdominis plane (OSTAP) block with 0.375% ropivacaine 20 mL on each side
Study: 34853883
Drug: Maternal bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal bone resorption (measured by urinary excretion of cross-linked N-telopeptides) during pregnancy
Study: 35531319
Drug: Intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia with tramadol
Study: 35531319
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Intravenous analgesia with sufentanil)
Study: 35869955
Drug: Controlled-release dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release dinoprostone vaginal insert
Study: 34562728
Drug: Cognitive training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive training plus treatment as usual
Study: 34580638
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine vs Placebo
Study: 34580638
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine vs Exenatide
Study: 35018648
Drug: Propofol target-controlled
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target-controlled infusion (TCI) with effect compartment concentration set to 3 μg/ml
Study: 34189335
Drug: Active deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active deep brain stimulation (DBS) targeting the ventral capsule/ventral striatum (VC/VS) region for three months
Study: 32342831
Drug: Dabigatran treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran treatment
Study: 36356989
Drug: Bictegravir (BIC)
DrugBank: Bictegravir (DB11799)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bictegravir (BIC) 50 mg/emtricitabine (FTC) 200 mg/tenofovir alafenamide (TAF) 25 mg (Biktarvy) taken two times per day
Study: 33345866
Drug: 20-mL liposomal
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-mL liposomal bupivacaine
Study: 33345866
Drug: 20-mL 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mL 0.25% plain bupivacaine
Study: 35798016
Drug: Cabozantinib 40
Normalized name: cabozantinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 40 mg orally once daily plus atezolizumab 1200 mg intravenously every 3 weeks
Study: 37499670
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg orally twice daily
Study: 35798016
Drug: Single-agent cabozantinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent cabozantinib 60 mg orally once daily
Study: 34598050
Drug: Parent-only social
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-only social learning Cognitive Behavioral Therapy (SLCBT)
Study: 34002707
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg mefenamic acid
Study: 32842971
Drug: TAU +
Normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU + FNC (Treatment as Usual + Informal Social Network Intervention)
Study: 32388522
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (diode laser, λ: 645 nm) administered for three consecutive days starting on day 1 (T0)
Study: 35512252
Drug: Rosuvastatin, 10
Normalized name: Ezetimibe-Rosuvastatin, 10 mg-5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin, 10 mg daily
Study: 35012310
Drug: PS-GOS-enriched beverage
Normalized name: Go-dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS-GOS-enriched beverage (2 g PS/day and 4.3 g GOS/day)
Study: 34918714
Drug: Aloe ferox
Normalized name: Aloe ferox leaf
DrugBank: Aloe ferox leaf (DB14257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe ferox (460 mg, 2 capsules/day for 2 weeks, followed by a 2-week break, repeated 3 times)
Study: 32894102
Drug: HIV-1-positive women,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1-positive women, treatment-naive, tested for transmitted drug resistance mutations (TDRM)
Study: 34523108
Drug: Prothrombin complex
Normalized name: prothrombin complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prothrombin complex concentrates (PCC); median dose 1,000 units
Study: 34523108
Drug: Frozen plasma
Normalized name: Fresh frozen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frozen plasma (FP); median dose 4 units
Study: 33303389
Drug: Nightly sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nightly sildenafil 50 mg and sildenafil 100 mg on demand for sexual relations (up to 6 pills/month)
Study: 33303389
Drug: Nightly sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nightly sildenafil 50 mg (5 nights/week) plus intracavernosal injections twice/week
Study: 33303389
Drug: Nightly placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nightly placebo with sildenafil 100 mg on demand for sexual relations (up to 6 pills/month)
Study: 38755585
Drug: Olaparib maintenance
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib maintenance therapy
Study: 32591103
Drug: Active surveillance
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active surveillance (no maintenance therapy)
Study: 32591103
Drug: Olaparib maintenance
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib maintenance therapy with 10% discount
Study: 32591103
Drug: Olaparib maintenance
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib maintenance therapy with 20% discount
Study: 32717350
Drug: Adaptive preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive preventive intervention (API) designed to educate and motivate heavy-drinking college students; specific details on dosage and duration not available.
Study: 32717350
Drug: Adaptive preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive preventive intervention (API); specific details on dosage and duration not available.
Study: 32792107
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy plus small changes lifestyle intervention
Study: 32107930
Drug: Insulin Degludec/Liraglutide
Normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin Degludec/Liraglutide (IDegLira)
Study: 32107930
Drug: Basal-Bolus (BB)
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal-Bolus (BB) therapy (once-daily insulin glargine 100 U/mL and insulin aspart ≤4 times/day)
Study: 32623059
Drug: Immersive tutorial
Normalized name: OCTOCRYLENE 10 g in 100 g / HOMOSALATE 10 g in 100 g / AVOBENZONE 3 g in 100 g / OCTISALATE 4.5 g in 100 g TOPICAL LOTION [Eucerin Face immersive Hydration]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immersive tutorial in virtual reality (VR) as a teaching supplement
Study: 33217593
Drug: Tamoxifen combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen combined with toremifene treatment
Study: 33272311
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy plus battlefield acupuncture
Study: 34942595
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium pre-exercise meals (1,000 mg)
Study: 34942595
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium pre-exercise meals (<50 mg)
Study: 34706268
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral hygiene advice (control)
Study: 34534233
Drug: Xanthine oxidase
Normalized name: Xanthine oxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthine oxidase inhibitors
Study: 33065552
Drug: ticagrelor/aspirin (carriers)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ticagrelor/aspirin (carriers)
Study: 33065552
Drug: clopidogrel/aspirin (carriers)
Approvals — FDA: no, EMA: no, PMDA: no
Description: clopidogrel/aspirin (carriers)
Study: 33065552
Drug: ticagrelor/aspirin (non-carriers)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ticagrelor/aspirin (non-carriers)
Study: 33065552
Drug: clopidogrel/aspirin (non-carriers)
Approvals — FDA: no, EMA: no, PMDA: no
Description: clopidogrel/aspirin (non-carriers)
Study: 32022618
Drug: Terbinafine hydrochloride
Normalized name: Terbinafine Hydrochloride
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbinafine hydrochloride spray (THS) in combination with 3% boric acid alcohol (3% BAA) ear drops
Study: 616826658
Drug: Daily diary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily diary control group
Study: 33709238
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM) involving triple rehabilitation therapy (electro‐acupuncture, Chinese medicinal herb fumigating‐washing, and traditional exercises)
Study: 33709238
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation therapy (physical factor therapy, joint movement training, and muscle strength training)
Study: 36187365
Drug: 12-week online
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week online multicomponent stress reduction intervention including yoga, breathwork, meditation videos, cognitive behavioral therapy activities, and check-ins.
Study: 36187365
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received weekly motivational messages by email.
Study: 33278859
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue injection with combination therapy
Study: 33278859
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue injection without combination therapy
Study: 33278859
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue injection (overall population)
Study: 34323681
Drug: lenabasum 5
Normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lenabasum 5 mg twice daily
Study: 34323681
Drug: lenabasum 20
Normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lenabasum 20 mg twice daily
Study: 35416465
Drug: 1000mg metamizole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg metamizole + 400mg ibuprofen
Study: 33609324
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of drug treatment quality by three specialist physicians and two resident physicians
Study: 33609324
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of the association between drug treatment and hospital admission
Study: 32842975
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and written information about a home-based exercise programme (Control)
Study: 34264860
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus normal dose of Chinese herbal fumigation steam therapy (CHFST)
Study: 34264860
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus one-sixteenth of a normal dose of CHFST
Study: 35125265
Drug: Group-based therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based therapy (GT)
Study: 35125265
Drug: Email-delivered self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Email-delivered self-help cognitive behavioral therapy (ESH)
Study: 34128526
Drug: Vehicle (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (normal saline) injections
Study: 34756640
Drug: High‐Intensity Laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: High‐Intensity Laser Therapy (HILT)
Study: 35404684
Drug: Fuzuloparib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzuloparib (150 mg, twice daily)
Study: 38140184
Drug: 23-valent pneumococcal
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Study: 33142249
Drug: Dexmedetomidine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.4 μg/ml
Study: 33142249
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 μg/ml
Study: 33142249
Drug: Dexmedetomidine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.6 μg/ml
Study: 33142249
Drug: Dexmedetomidine 0
Normalized name: dexmedetomidine 0.12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0 μg/ml
Study: 33142249
Drug: Dexmedetomidine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.3 μg/ml
Study: 39251616
Drug: Norepinephrine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine administration
Study: 33031148
Drug: Clinically important
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically important treatment benefit or harm
Study: 35907504
Drug: Low-dose Prasugrel
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Prasugrel or Clopidogrel
Study: 34668436
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g of ketone ester (KE)
Study: 34668436
Drug: 300 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/kg body mass bicarbonate (BIC)
Study: 34668436
Drug: Control drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drink with 60 g of carbohydrates/h
Study: 36102630
Drug: 2-week postoperative
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week postoperative oral antibiotics
Study: 36102630
Drug: 12-week postoperative
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week postoperative oral antibiotics
Study: 33714226
Drug: Intensive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemic control (exenatide and pioglitazone or basal-bolus insulin)
Study: 35538000
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral and written information
Study: 35538000
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral and written information plus additional educational video
Study: 32976051
Drug: Olive pâté
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive pâté (4 tablets/day corresponding to 30 mg/day of hydroxytyrosol)
Study: 32232698
Drug: Tailored dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored dose-dense chemotherapy (four cycles of epirubicin and cyclophosphamide every 2 weeks followed by four cycles of docetaxel every 2 weeks)
Study: 32232698
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (three cycles of fluorouracil and epirubicin-cyclophosphamide every 3 weeks followed by three cycles of docetaxel every 3 weeks)
Study: 33428901
Drug: Extracorporeal life
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal life support (ECLS) in addition to early revascularization with percutaneous coronary intervention or coronary artery bypass grafting and optimal medical treatment
Study: 36173031
Drug: Synbiotics capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotics capsule plus anti-inflammatory-antioxidant rich diet
Study: 36173031
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule plus dietary recommendations
Study: 34184929
Drug: Testosterone levels
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone levels during androgen deprivation therapy (ADT)
Study: 35373693
Drug: NB‐UVB monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NB‐UVB monotherapy
Study: 32216909
Drug: Alteplase 20
Normalized name: alteplase 20 mg INTRAVEN VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase 20 mg
Study: 32216909
Drug: Alteplase 10
Normalized name: alteplase 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase 10 mg
Study: 33334450
Drug: High-dose Dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Dobutamine (DBT) (40 to 50 μg/kg/min for 10 min)
Study: 33334450
Drug: High-dose Isoproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Isoproterenol (IPN) (20 to 30 μg/min for 10 min)
Study: 33592825
Drug: Modified selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified selective spinal massage method combined with basic rehabilitation treatment
Study: 33592825
Drug: Basic rehabilitation
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic rehabilitation treatment
Study: 35689890
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (2000 mg/d)
Study: 35689890
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (2000 mg/d) in male participants
Study: 35689890
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (2000 mg/d) in female participants
Study: 33075197
Drug: 10% sinecatechins
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sinecatechins ointment applied three times daily for 16 weeks
Study: 33075197
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment applied three times daily for 16 weeks
Study: 32899037
Drug: Mirogabalin 10
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 10 or 15 mg twice daily (BID)
Study: 32052264
Drug: Mirogabalin 15
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 15 mg BID
Study: 32899037
Drug: Mirogabalin (flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirogabalin (flexible dosing)
Study: 36472718
Drug: Square-wave insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Square-wave insulin bolus (SQ)
Study: 32007123
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) applied post-surgery, maintaining negative pressure at -125 mmHg for five days.
Study: 32200266
Drug: Immediate oral
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate oral intake of low-fat solid food (15 g/d)
Study: 35026964
Drug: Sham ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ultrasound treatment (Control)
Study: 33338325
Drug: Multimodal occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal occupational therapy (including patient education, hand exercises, orthoses, and assistive devices)
Study: 33338325
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (OA information)
Study: 35045228
Drug: SER-109 (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: SER-109 (four capsules daily for 3 days)
Study: 35045228
Drug: Placebo (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (four capsules daily for 3 days)
Study: 33051650
Drug: Amphotericin monotherapy
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin monotherapy
Study: 32206786
Drug: 6-month regimen
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month regimen alternating intravenous and oral glucocorticoids with an alkylating agent every other month
Study: 32206786
Drug: Cyclical therapy
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical therapy (glucocorticoids and alkylating agent)
Study: 32206786
Drug: Mycophenolate salts
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolate salts and adrenocorticotropic hormone
Study: 34499904
Drug: Antibiotic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic group (3 g of ampicillin-sulbactam administered just before, 8 hours after, and the morning after ESD)
Study: 34499904
Drug: Nonantibiotic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonantibiotic group (conventional treatment)
Study: 33180897
Drug: Alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatment options for hypertension (HTN)
Study: 33180897
Drug: Alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatment options for type II diabetes mellitus (T2DM)
Study: 33180897
Drug: Alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatment options for hyperlipidemia (HL)